Role of e-cigarettes and pharmacotherapy during attempts to quit cigarette smoking: The PATH Study 2013-16

John P Pierce, Tarik Benmarhnia, Ruifeng Chen, Martha White, David B Abrams, Bridget K Ambrose, Carlos Blanco, Nicolette Borek, Kelvin Choi, Blair Coleman, Wilson M Compton, K Michael Cummings, Cristine D Delnevo, Tara Elton-Marshall, Maciej L Goniewicz, Shannon Gravely, Geoffrey T Fong, Dorothy Hatsukami, James Henrie, Karin A Kasza, Sheila Kealey, Heather L Kimmel, Jean Limpert, Raymond S Niaura, Carolina Ramôa, Eva Sharma, Marushka L Silveira, Cassandra A Stanton, Michael B Steinberg, Ethel Taylor, Maansi Bansal-Travers, Dennis R Trinidad, Lisa D Gardner, Andrew Hyland, Samir Soneji and Karen Messer

PLOS ONE, 2020, vol. 15, issue 9, 1-16

Abstract: Background: More smokers report using e-cigarettes to help them quit than FDA-approved pharmacotherapy. Objective: To assess the association of e-cigarettes with future abstinence from cigarette and tobacco use. Design: Cohort study of US sample, with annual follow-up. Participants: US adult (ages 18+) daily cigarette smokers identified at Wave 1 (W1; 2013–14) of the PATH Study, who reported a quit attempt before W2 and completed W3 (n = 2443). Exposures: Use of e-cigarettes, pharmacotherapy (including nicotine replacement therapy), or no product for last quit attempt (LQA), and current daily e-cigarette use at W2. Analysis: Propensity score matching (PSM) of groups using different methods to quit. Outcome measures: 12+ months abstinence at W3 from cigarettes and from all tobacco (including e-cigarettes). 30+ days abstinence at W3 was a secondary outcome. Results: Among daily smokers with an LQA, 23.5% used e-cigarettes, 19.3% used pharmacotherapy only (including NRT) and 57.2% used no product. Cigarette abstinence for 12+ months at W3 was ~10% in each group. Half of the cigarette abstainers in the e-cigarette group were using e-cigarettes at W3. Different methods to help quitting had statistically comparable 12+ month cigarette abstinence at W3 (e-cigarettes vs no product: Risk Difference (RD) = 0.01, 95% CI: -0.04 to 0.06; e-cigarettes vs pharmacotherapy: RD = 0.02, 95% CI:-0.04 to 0.09). Likewise, daily e-cigarette users at W2 did not show a cessation benefit over comparable no-e-cigarette users and this finding was robust to sensitivity analyses. Abstinence for 30+ days at W3 was also similar across products. Limitations: The frequency of e-cigarette use during the LQA was not assessed, nor was it possible to assess continuous abstinence from the LQA. Conclusion: Among US daily smokers who quit cigarettes in 2014–15, use of e-cigarettes in that attempt compared to approved cessation aids or no products showed similar abstinence rates 1–2 years later.

Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0237938 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 37938&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0237938

DOI: 10.1371/journal.pone.0237938

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().